SLFN11 and familial pancreatic carcinoma: By contrast, combinations with other DDRi (ATMi, olaparib) or other combination strategies (e.g., DDRi (ATRi/WEE1i) + non-DDAi (MEKi used as a representative example)) had the same effect in SLFN11 high and low pancreatic cancer cell lines (Fig. 6a and Supplementary Fig. S8A).